<?xml version="1.0" encoding="UTF-8"?>
<p>Patients with deterioration of CIDP during the washout phase (ie, those with active disease) will be randomised to receive study treatment. Deterioration is defined as a decrease in the patients' global impression of change (PGIC) scale plus one of the following: (1) an increase of ≥1 point on the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score,
 <xref rid="jns12267-bib-0006" ref-type="ref">6</xref> (2) a decrease of ≥8 kPa in grip strength in one hand,
 <xref rid="jns12267-bib-0015" ref-type="ref">15</xref> or (3) an Inflammatory Rasch‐built Overall Disability Scale (I‐RODS) minimum clinically important difference SE (MCID‐SE) cut‐off of −1.96 or less.
 <xref rid="jns12267-bib-0016" ref-type="ref">16</xref>, 
 <xref rid="jns12267-bib-0017" ref-type="ref">17</xref>
</p>
